CHOLESTEROL ABSORPTION INHIBITOR (AZETIDINONE) AND OMEGA 3 FATTY ACIDS (EPA, DHA, DPA) FOR THE REDUCTION OF CHOLESTEROL AND FOR THE REDUCTION OF CARDIOVASCULAR EVENTS
A composition and a method of treatment utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DP A) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. EPA + DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition. The formulation may further contain specific amounts of arachidonic acid (AA) and of omega-3 fatty acids having 18 carbon atoms, including one or more of stearidonic acid (SDA) and alpha-linolenic acid (ALA). The application further teaches methods of administering such combinations, and is directed towards unit dosages of such combinations for the reduction of risk factors for cardiovascular disease.La présente invention concerne une composition et un procédé de traitement utilisant une combinaison dinhibiteurs de labsorption du cholestérol hypolipémiants, par exemple, des azétidinones, avec des mélanges dune formulation dacides gras oméga 3 contenant environ 90 % en poids ou plus dacides gras oméga 3 y compris une combinaison dacide eicosapentaénoïque (EPA), dacide docosapentaénoïque (DPA) et dacide docosahexaénoïque (DHA) en un rapport en poids dEPA/DHA de 5,7 à 6,3, la somme de lEPA, du DHA et du DPA représentant environ 82 % en poids de la formulation totale et environ 92 % de la teneur en acide gras oméga 3 totale de la composition. LEPA + le DHA constituent environ 80 % de la formulation totale et environ 89 % de la teneur en acide gras oméga 3 de la composition. La formulation peut en outre contenir des quantités spécifiques dacide arachidonique (AA) et daci
